$ENDP Endo International (ENDP) Scheduled to Post
Post# of 109

by - American Banking and Market News

Endo International (NASDAQ:ENDP) (TSE:ENL) is scheduled to be releasing its earnings data before the market opens on Tuesday, May 8th. Analysts expect Endo International to post earnings of $0.55 per share for the quarter. Endo International has set its FY18 guidance at $2.15-2.55 EPS.
Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $0.77 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.62 by $0.15. The business had revenue of $768.64 million for the quarter, compared to analysts' expectations of $762.29 million. Endo International had a positive return on equity of 81.03% and a negative net margin of 58.68%. The business's revenue was down 38.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.77 EPS. On average, analysts expect Endo International to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Endo International stock opened at $5.73 on Tuesday. The company has a current ratio of 1.02, a quick ratio of 0.85 and a debt-to-equity ratio of 17.00. The company has a market cap of $1,340.04, a price-to-earnings ratio of 1.56 and a beta of 0.38. Endo International has a fifty-two week low of $5.27 and a fifty-two week high of $14.15.
ENDP has been the topic of a number of analyst reports. Mizuho reissued a "buy" rating and issued a $12.00 price target (down from $14.00) on shares of Endo International in a research report on Wednesday, January 3rd. Leerink Swann initiated coverage on Endo International in a research report on Tuesday, January 2nd. They issued an "outperform" rating and a $12.00 price target on the stock. Cantor Fitzgerald set a $7.00 price target on Endo International and gave the stock a "hold" rating in a research report on Thursday, January 11th. Zacks Investment Research cut Endo International from a "hold" rating to a "sell" rating in a research report on Monday, January 15th. Finally, BidaskClub cut Endo International from a "hold" rating to a "sell" rating in a research report on Thursday, January 11th. Four equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. Endo International currently has a consensus rating of "Hold" and a consensus target price of $9.40.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
The views expressed in any and all content distributed by Newstex and its re-distributors (collectively, the "Newstex Authoritative Content"

Source: Online Publications (April 30, 2018 - 8:00 PM EDT)
News by QuoteMedia
www.quotemedia.com


Endo International plc (ENDPQ) Stock Research Links
Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW
CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment